Research-only content. This comparison is for educational purposes and does not constitute medical advice. Read full disclaimer →

CJC-1295 vs Ipamorelin

Last updated: 2026-05-27

CJC-1295 is a GHRH analog that stimulates growth hormone release from the pituitary; Ipamorelin is a ghrelin mimetic (GHRP) that acts on a different receptor.
CJC-1295 produces sustained GH elevation over hours; Ipamorelin produces shorter, more pulsatile GH release.
Ipamorelin is considered more selective with fewer effects on cortisol and prolactin compared to other GHRPs.
Both are studied for body composition, recovery, and age-related GH decline.
They are sometimes studied together due to potentially complementary mechanisms of GH secretion.

CJC-1295 and Ipamorelin both promote growth hormone release but act through different receptor pathways and produce distinct GH release patterns.

Side-by-Side Comparison

Attribute	CJC-1295	Ipamorelin
What It Is	A growth hormone releasing hormone analog studied for stimulating growth hormone secretion.	A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
Typical Research Focus
Proposed Mechanisms	Binds to GHRH receptors on anterior pituitary somatotrophs Drug Affinity Complex (DAC) binds albumin, extending half-life to ~6–8 days Stimulates pulsatile GH release, preserving natural secretion patterns	Binds ghrelin receptor (GHSR) on pituitary somatotroph cells to stimulate pulsatile GH release Selective GH stimulation without significant cortisol, ACTH, prolactin, or aldosterone elevation Dose-dependent GH response that preserves natural circadian GH pulsatility
Evidence Snapshot	Medium Evidenceresearch peptide	Medium Evidenceresearch peptide
Cautions	May affect blood sugar levels Potential for water retention reported in studies Not FDA-approved for any indication	Limited long-term human safety data Not FDA-approved May interact with other hormonal therapies

CJC-1295

What It Is: A growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
Research Focus
Evidence: Medium Evidence
Cautions: May affect blood sugar levels

Potential for water retention reported in studies

Not FDA-approved for any indication

Ipamorelin

What It Is: A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
Research Focus
Evidence: Medium Evidence
Cautions: Limited long-term human safety data

Not FDA-approved

May interact with other hormonal therapies

When Researchers Compare Them

CJC-1295 and Ipamorelin are frequently discussed together in growth hormone research because they stimulate GH release through complementary pathways. CJC-1295, a growth hormone-releasing hormone (GHRH) analog, acts on the GHRH receptor to promote sustained GH secretion. Ipamorelin, a growth hormone-releasing peptide (GHRP), acts on the ghrelin receptor (GHS-R1a) to produce more targeted GH pulses.

Researchers note that Ipamorelin is considered one of the more selective GHRPs, meaning it tends to stimulate GH release without significantly affecting cortisol or prolactin levels — a distinction from older secretagogues like GHRP-6. CJC-1295, particularly the DAC (Drug Affinity Complex) variant, extends the half-life of GHRH signaling.

Some preclinical and early-phase research has explored whether combining GHRH analogs with GHRPs produces synergistic GH elevation, reflecting the body's natural dual-signal system for GH regulation.

Peptide Profiles

CJC-1295 Profile Ipamorelin Profile

Citations

[1] Teichman SL. et al. — Prolonged stimulation of growth hormone release by CJC-1295. J Clin Endocrinol Metab. 2006 Source
[2] Teichman SL. et al. — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. JCEM. 2006 Source